Disease Markers

Disease Markers / 2018 / Article

Review Article | Open Access

Volume 2018 |Article ID 7565834 | 12 pages | https://doi.org/10.1155/2018/7565834

A Matrix Metalloproteinase-1 Polymorphism, MMP1–1607 (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients

Academic Editor: Michael Hawkes
Received27 Jun 2018
Revised23 Sep 2018
Accepted26 Sep 2018
Published02 Dec 2018

Abstract

Although the matrix metalloproteinase-1 (MMP1) polymorphism MMP1–1607 (1G>2G) has been associated with susceptibility to various cancers, these findings are controversial. Therefore, we conducted this meta-analysis to explore the association between MMP1–1607 (1G>2G) and cancer risk. A systematic search of literature through PubMed, Embase, ISI Web of Knowledge, and Google Scholar yielded 77 articles with 21,327 cancer patients and 23,245 controls. The association between the MMP1–1607 (1G>2G) polymorphism and cancer risks was detected in an allele model (2G vs. 1G, overall risk [OR]: 1.174, 95% confidence interval [CI]: 1.107–1.244), a dominant model (2G2G/1G2G vs. 1G1G OR, OR: 1.192, 95% CI: 1.090–1.303), and a recessive model (2G2G vs. 1G2G/1G1G, OR: 1.231, 95% CI: 1.141–1.329). In subgroup analysis, these associations were detected in both Asians and Caucasians. After stratification by cancer types, associations were found in lung, colorectal, nervous system, renal, bladder, and nasopharyngeal cancers. This meta-analysis revealed that MMP1–1607 (1G>2G) polymorphism was significantly associated with elevated risk of cancers.

1. Introduction

Single-nucleotide polymorphisms (SNP) are variations in single nucleotides that occur at specific positions in the genome and influence protein structure, gene splicing, transcription factor binding, messenger RNA degradation, or sequences of noncoding RNAs [1]. SNPs reportedly contribute to interindividual variability in susceptibility to common diseases such as cancer.

Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes that can degrade extracellular matrix components, thereby affecting various physiological and pathological processes such as embryonic development, wound healing, arthritis, atherosclerosis, and tumor progression [2]. Increasing evidence shows that MMPs play significant roles in cancer development, including cell growth, differentiation, apoptosis, angiogenesis, invasion, and metastasis [3].

MMP1, a member of the MMP family, can degrade interstitial collagen types I, II, and III, clearing a path for cancer cells to invade matrix barriers and migrate through tissue stroma [4]. The MMP1 gene is located at 11q22.3, and MMP1 expression can be regulated by the MMP1 promoter. The gene polymorphism MMP1–1607 (1G>2G) or rs1799750 in the MMP1 promoter has been associated with increased susceptibility for various cancers [5, 6]. However, the results were controversial because of variations in cancer types and patient demographics. Therefore, we conducted this meta-analysis to further explore the association between MMP1–1607 (1G>2G) polymorphism and cancer susceptibility.

2. Materials and Methods

2.1. Identification and Eligibility of Studies

We conducted a systematic search of literature published until December 2017 that investigated the association of MMP1–1607 (1G>2G) polymorphism with cancer risks, through PubMed, Embase, ISI Web of Knowledge, and Google Scholar, using the terms “Matrix metalloproteinase-1 or MMP-1 or rs1799750,” “polymorphism or variation or mutation or SNP,” and “cancer or carcinoma or tumor or neoplasm.” Only case–control studies with sufficient genotype distribution data to calculate odds ratios (ORs) with 95% confidence interval (CIs) in different gene models were included. Letters, case reports, animal studies, and reviews were excluded. When overlapping populations were included in different articles, only the publication with the largest sample size was selected.

2.2. Data Extraction

Two investigators independently reviewed the articles to exclude irrelevant and overlapping studies. The following data were extracted from eligible publications: first author, published year, cancer type, country, ethnicity, control source, genotyping method, and genotype distribution. Any disagreements were resolved by discussion or by consultation with another investigator.

2.3. Statistical Analysis

The meta-analysis was conducted using SATAT (version 13.0). The Hardy–Weinberg equilibrium (HWE) for control groups was checked by the chi-square goodness-of-fit test () The associations between MMP1–1607 (1G>2G) polymorphism and cancer risks were calculated by OR and 95% CI with the following models to avoid assuming only one suboptimal genetic model: an allele model (2G vs. 1G), a dominant model (2G2G/1G2G vs. 1G1G), and a recessive model (2G2G vs. 1G2G/1G1G). Subgroup analyses were performed by cancer type and ethnicity.

The heterogeneity of studies was assessed by test using value and value. A fixed-effects model was adopted when test indicated a lack of heterogeneity (); otherwise, a random-effects model was used. We considered 0–40% of value to indicate low heterogeneity, 30–60% to indicate moderate heterogeneity, 50–90% to indicate substantial heterogeneity, and 75–100% to indicate considerable heterogeneity. Publication bias was measured with funnel plots and Harbord’s and Peter’s tests.

3. Results

3.1. Characteristics of Eligible Studies

The study selection procedure is shown in Figure 1. We included 77 articles with 21,327 cancer patients and 23,245 controls in this meta-analysis (Table 1) [783]. Of these, 43 articles were conducted among Asian populations and 34 among Caucasian populations; 67 studies were hospital-based and 10 were population-based. Of the different genotyping methods used in these studies, 45 used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), 18 used TaqMan real-time PCR, 8 used sequencing, and 6 used other methods. Sixteen of the 77 articles showed deviations from HWE in control groups.


AuthorYearCancer typeCountryEthnicityControlGenotype of case of controlHWE (P)

Kanamori et al. [7]1999Ovarian cancerJapanAsianHBPCR-RFLP1631500.033
Biondi et al. [8]2000Other cancerItalyCaucasianHBTaqMan1601640.813
Nishioka et al. [9]2000Endometrial cancerJapanAsianHBSequencing1001500.033
Ye et al. [10]2001Cutaneous melanomaEnglandCaucasianHBTaqMan1391320.849
Zhu et al. [11]2001Lung cancerAmericaCaucasianHBPCR-RFLP4564510.028
Ghilardi et al. [12]2002Breast cancerAmericaCaucasianHBSequencing861100.652
Hinoda et al. [13]2002Colorectal cancerJapanAsianPBPCR-RFLP1011270.949
Hirata et al. [14]2003Renal cell cancerJapanAsianHBSequencing1192100.993
Nishioka et al. [15]2003Endometrial cancerJapanAsianHBSequencing1091500.033
Wenham et al. [16]2003Ovarian cancerAmericaCaucasianPBTaqMan3113870.536
Hashimoto et al. [17]2004Head and neck cancerJapanAsianHBPCR-RFLP1402230.852
Hirata et al. [18]2004Renal cell cancerJapanAsianPBPCR-RFLP1562300.871
Lin et al. [19]2004Oral cancerTaiwanAsianHBSequencing1211470.336
Matsumura et al. [20]2004Gastric cancerJapanAsianHBPCR-RFLP2151660.432
Zinzindohoué et al. [21]2004Head and neck cancerFranceCaucasianHBPCR-RFLP1252490.978
Fang et al. [22]2005Lung cancerChinaAsianHBPCR-RFLP2433500.000
Jin et al. [23]2005Gastric cancerChinaAsianHBPCR-RFLP4173500.000
Ju et al. [24]2005Cervical cancerKoreaAsianHBTaqMan2323320.695
Lai et al. [25]2005Cervical cancerTaiwanAsianHBOther1971971.000
McCready et al. [26]2005GlioblastomaAmericaCaucasianHBPCR-RFLP81570.916
Cao and Li [27]2006Oral cancerChinaAsianHBPCR-RFLP961200.657
Elander et al. [28]2006Colorectal cancerSwedenCaucasianHBOther1272080.918
Kader et al. [29]2006Bladder cancerAmericaCaucasianHBTaqMan5565550.565
Li et al. [30]2006Ovarian cancerChinaAsianHBPCR-RFLP1221510.008
Lièvre et al. [31]2006Colorectal cancerFranceCaucasianHBOther5915610.900
O-charoenrat et al. [32]2006Head and neck cancerThailandAsianHBPCR-RFLP3003000.988
Su et al. [33]2006Lung cancerAmericaCaucasianPBTaqMan201413230.597
Sugimoto et al. [34]2006Endometrial cancerJapanAsianHBPCR-RFLP1072130.768
Xu et al. [35]2006Colorectal cancerChinaAsianHBOther1261260.938
Albayrak et al. [36]2007Prostate cancerTurkeyCaucasianHBPCR-RFLP55430.000
Ju et al. [37]2007Ovarian cancerKoreaAsianHBTaqMan1333320.695
Lei et al. [38]2007Breast cancerSwedenCaucasianPBTaqMan9549470.151
Lu et al. [39]2007Other cancerChinaAsianHBPCR-RFLP2213660.000
Nasr et al. [40]2007Nasopharyngeal cancerTunisiaCaucasianHBPCR-RFLP1741710.091
Nishizawa et al. [41]2007Oral cancerJapanAsianHBTaqMan1701640.493
Piccoli et al. [42]2007Renal cell carcinomaBrazilCaucasianPBPCR-RFLP991181.000
Vairaktaris et al. [43]2007Oral cancerGreekCaucasianHBPCR-RFLP1561410.276
Woo et al. [44]2007Colorectal cancerKoreaAsianHBPCR-RFLP1853040.488
Zhai et al. [45]2007Hepatocellular cancerChinaAsianHBSequencing4314790.559
Zhou et al. [46]2007Nasopharyngeal cancerChinaCaucasianPBSequencing8297590.634
Dos Reis et al. [47]2008Prostate cancerBrazilCaucasianPBTaqMan1001000.293
González-Arriaga et al. [48]2008Lung cancerSpainCaucasianHBPCR-RFLP5015100.934
Kouhkan et al. [49]2008Colorectal cancerIranAsianHBPCR-RFLP1501000.935
Shimizu et al. [50]2008Tongue cancerJapanAsianHBTaqMan69910.585
Tasci et al. [51]2008Bladder cancerTurkeyCaucasianHBPCR-RFLP102940.740
Bradbury et al. [52]2009Esophageal cancerAmericaCaucasianHBTaqMan3134500.508
de Lima et al. [53]2009Colorectal cancerBrazilCaucasianHBPCR-RFLP1081080.258
dos Reis et al. [54]2009Prostate cancerBrazilCaucasianHBTaqMan1001000.293
Ricketts et al. [55]2009Renal cell cancerPolishCaucasianHBTaqMan3233140.847
Srivastava et al. [56]2010Bladder cancerIndiaAsianHBPCR-RFLP2002000.190
Tsuchiya et al. [57]2009Prostate cancerJapanAsianPBSequencing2832510.285
Vairaktaris et al. [58]2009Oral cancerGreekCaucasianHBPCR-RFLP1561410.276
Altaş et al. [59]2010Other cancerTurkeyCaucasianHBPCR-RFLP30300.195
Chaudhary et al. [60]2010Head and neck cancerIndiaAsianHBPCR-RFLP4224260.240
Fang et al. [61]2010Colorectal cancerChinaAsianHBPCR-RFLP2372520.683
Okamoto et al. [62]2010Hepatocellular cancerJapanAsianHBPCR-RFLP91820.009
Hart et al. [63]2011Lung cancerNorwayCaucasianPBTaqMan4364340.218
Liu et al. [64]2011Lung cancerChinaAsianHBPCR-RFLP8258250.924
Malik et al. [65]2011GlioblastomaIndiaAsianHBPCR-RFLP1101500.433
Wang et al. [66]2011Cutaneous melanomaAmericaCaucasianHBTaqMan8648490.940
Cheung et al. [67]2012Esophageal cancerCanadaCaucasianHBTaqMan3092790.974
Enewold et al. [68]2012Lung cancerAmericaCaucasianHBOther711470.743
Fakhoury et al. [69]2012Lung cancerLebanonCaucasianHBPCR-RFLP41510.218
Wieczorek et al. [70]2013Bladder cancerPolandCaucasianHBTaqMan2401990.022
Brzóska et al. [71]2014Lung cancerPolandCaucasianHBPCR-RFLP53540.264
Dedong et al. [72]2014Gastric cancerChinaAsianHBOther4224280.546
Devulapalli et al. [73]2014Gastric cancerIndiaAsianHBPCR-RFLP1662020.000
Dey et al. [74]2014Gastric cancerIndiaCaucasianHBPCR-RFLP1451450.850
Guan et al. [75]2014Esophageal cancerChinaAsianHBPCR-RFLP1321320.989
Kawal et al. [76]2016Breast cancerTaiwanAsianHBPCR-RFLP123212320.004
Pei et al. [77]2016Other cancerTaiwanAsianHBPCR-RFLP2662660.258
Su et al. [78]2016Breast cancerTaiwanAsianHBPCR-RFLP123212320.004
Sun et al. [79]2016Oral cancerTaiwanAsianHBPCR-RFLP7889560.029
Tsai et al. [80]2016Nasopharyngeal cancerTaiwanAsianHBPCR-RFLP1763520.278
Lai et al. [81]2017Hepatocellular cancerTaiwanAsianHBPCR-RFLP2988890.008
Padala et al. [82]2017Breast cancerIndiaAsianHBPCR-RFLP3003000.015
Yang et al. [83]2017Gastric cancerTaiwanAsianHBPCR-RFLP1213630.131

HWE: Hardy–Weinberg equilibrium.
3.2. Quantitative Analysis

The main results of this meta-analysis are listed in Table 2. The association between the MMP1–1607 (1G>2G) polymorphism and cancer risks was seen in the allele model (2G vs. 1G, OR: 1.174, 95% CI: 1.107–1.244; Figure 2), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.192, 95% CI: 1.090–1.303; Figure 3), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.231, 95% CI: 1.141–1.329; Figure 4).


2g vs. 1g2g2g–1g2g vs. 1g1g2g2g vs. 1g1g–1g2g
ORUCILCIORUCILCIORUCILCI

Overall771.1741.1071.2440.00074.0%1.1921.0901.3030.00062.4%1.2311.1411.3290.00067.5%
Cancer types
 Lung cancer91.1281.0021.2690.00663.1%1.1271.0051.2640.3658.4%1.1530.9531.3950.00268.1%
 Colorectal cancer81.2791.0871.5050.03553.6%1.2811.0331.5880.3658.5%1.3681.0941.7120.04152.1%
 Gastric cancer61.1060.9641.2680.16536.3%1.2210.8841.6870.06152.6%1.1210.9671.3000.4480.0%
 Oral cancer61.1210.8491.4810.00081.8%1.2540.7901.9910.00175.9%1.1080.8071.5210.00372.3%
 Nervous system cancer51.7991.4932.1680.8690.0%2.0701.4742.9060.4380.0%1.9351.4982.5010.4750.0%
 Ovarian cancer41.0220.8881.1760.8450.0%1.0900.7691.5450.17439.7%1.0130.8231.2470.4170.0%
 Breast cancer41.1940.9041.5760.00089.6%1.3520.9062.0170.00084.9%1.1490.8091.6320.00084.7%
 Renal cancer41.3511.1491.5900.32812.8%1.1790.8981.5470.8290.0%1.6741.3512.0730.5800.0%
 Bladder cancer41.4370.9602.1520.00089.2%1.3490.7712.3600.00183.1%1.7391.0742.8160.00181.7%
 Prostate cancer40.9320.4851.7910.00090.3%1.1360.4932.6160.00182.5%0.7800.3751.6230.00182.3%
 Head and neck cancer40.9580.5951.5430.00092.6%0.6780.3881.1860.00181.1%1.0710.5392.2190.00092.4%
 Endometrial cancer31.1470.7561.7410.02074.4%1.3120.4923.4970.00581.0%1.0910.8071.4760.32012.3%
 Nasopharyngeal cancer31.2121.0671.3770.3407.4%1.2990.9961.6960.31912.5%1.2651.0741.4880.5350.0%
 Hepatocellular cancer30.9950.8751.1310.8900.0%0.8160.6311.0550.3339.0%1.1180.9321.3410.4280.0%
 Esophageal cancer31.1890.8991.5720.03969.1%1.3210.9081.9220.13849.5%1.2600.8661.8350.08060.4%
 Other cancers71.1721.0101.3600.04353.8%1.1280.9031.4100.16734.2%1.2781.0381.5730.07348.0%
Ethnicity
 Asian431.2281.1301.3340.00975.2%1.2561.0841.4560.00068.9%1.2971.1761.4310.00066.4%
 Caucasian341.1091.0231.2020.00971.2%1.1261.0151.2490.00050.1%1.4311.0131.2890.00067.2%

n: number of comparison; P: value of test for heterogeneity test; UCI: upper limit of the 95% confidence interval; LCI: lower limit of the 95% confidence interval.
3.3. Risk by Cancer Type

When we considered different cancer types, elevated risk was found in lung cancer in the allele model (2G vs. 1G, OR: 1.128, 95% CI: 1.002–1.268) and the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.127, 95% CI: 1.005–1.264).

Significant association was also found in colorectal cancer in the allele model (2G vs. 1G, OR: 1.279, 95% CI: 1.087–1.505), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.281, 95% CI: 1.033–1.588), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.368, 95% CI: 1.094–1.712).

Five articles addressed the MMP1–1607 polymorphism in nervous system cancers, including astrocytoma, glioblastoma, hypophyseal adenoma, and malignant gliomas. Significantly elevated risks were observed in all the three different models (2G vs. 1G, OR: 1.799, 95% CI: 1.493–2.168; 2G2G/1G2G vs. 1G1G, OR: 2.070, 95% CI: 1.474–2.906; and 2G2G vs. 1G2G/1G1G, OR: 1.935, 95% CI: 1.498–2.501).

In renal cancer, the association was found in the allele model (2G vs. 1G: OR: 1.351, 95% CI: 1.149–1.590) and the recessive model (2G2G vs. 1G2G/1G1G OR: 1.674, 95% CI: 1.351–2.073). In bladder cancer, only in the recessive model was significant association detected (2G2G vs. 1G2G/1G1G, OR: 1.739, 95% CI: 1.074–2.816).

Increased risk was also found in nasopharyngeal cancer in the allele model (2G vs. 1G, OR: 1.212, 95% CI: 1.067–1.377) and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.267, 95% CI: 1.074–1.488).

No relationship was observed in gastric cancer, oral cancer, ovarian cancer, breast cancer, prostate cancer, head and neck cancer, endometrial cancer, hepatocellular cancer, or esophageal cancer (Table 2).

3.4. Risk by Ethnicity

In the Asian population, the association between the variation and cancer risks was detected in the allele model (2G vs. 1G, OR: 1.228, 95% CI: 1.130–1.334), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.256, 95% CI: 1.084–1.456), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.297, 95% CI: 1.176–1.431). In the Caucasian population, evaluated risk was also found in the allele model (2G vs. 1G, OR: 1.109, 95% CI: 1.023–1.202), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.126, 95% CI: 1.015–1.249), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.431, 95% CI: 1.013–1.289). Although significant differences were observed in both Asian and Caucasian populations, the Asian population showed higher risk than the Caucasian for the allele, dominant model, or homozygous model, but showed a decreasing trend in the recessive model (Table 2).

3.5. Heterogeneity and Sensitivity Analysis

Heterogeneity was observed in overall analyses in all comparison models with and range from 50.2% to 74.0% (indicating moderate or substantial heterogeneity). We therefore used the random-effects model. Sensitivity analysis to assess influence of individual studies showed no individual study to greatly affect the pooled OR.

3.6. Publication Bias

The forest plot seemed to be symmetrical (Figure 5). Harbord’s and Peter’s tests revealed no statistical significance in publication bias (Harbord’s: ; Peter’s: ).

4. Discussion

The MMP1–1607 (1G>2G) polymorphism has been associated with increased transcription of MMP1 due to an insert of a guanine base that creates a core-binding site for the EST family of transcription factors, which leads to increased susceptibility for tumor occurrence and progress. The significant association between the variation of MMP1–1607 (1G>2G) with some cancer types has been reported by different meta-analyses [3, 4, 8486].

In the current meta-analysis of 77 articles with 21,327 cancer patients and 23,245 controls, the MMP1–1607 (1G>2G) polymorphism was a strong risk factor in various cancers. Although both Asian and Caucasian individuals with 2G alleles or 2G2G genotypes may be more susceptible to cancer development, several studies revealed significant associations in Asians, but not Caucasians [5, 6]. These discrepancies might be due to limited sample sizes. Moreover, the Asian population seemed to show increased risk compared with Caucasian populations when the allele or dominant models were adopted, whereas a decreasing trend was observed in a recessive model, which implies different susceptibilities.

The association was found in lung, colorectal, nervous system, renal, bladder, and nasopharyngeal cancers, but not gastric, oral, ovarian, breast, prostate, head-and-neck, endometrial, hepatocellular, or esophageal cancers, which indicates that the variation plays different roles in various cancers, in accordance with pervious meta-analyses [4, 85, 87, 88]. However, these papers only focused on single types of cancer or one specific ethnicity. Our meta-analysis included all the cancers, analyzed the overall pooled OR, and performed subgroup analyses. Our findings imply a complex relationship between cancer susceptibility and gene variation, influenced by cancer sites and ethnicities.

Recently, the functional studies of SNPs have moved fast. For instance, a study reported that a missense variant rs149418249 in the TPP1 gene confers colorectal cancer risk by interrupting TPP1–TIN2 interaction and influencing telomere length [89]. An expression quantitative trait locus-based analysis revealed that a mutation rs27437, residing in the upstream of SLC22A5, can affect colorectal cancer risk by regulating SLC22A5 expression [90]. Another article reported that a TCF7L2 missense variant rs138649767 associates with colorectal cancer risk by interacting with a GWAS-identified regulatory variant rs698326 in the MYC enhancer [91]. However, the biological mechanisms of functional SNPs still remain challenging. Therefore, further studies are required to promulgate the real functions by which the MMP1–1607 (1G>2G) polymorphism may influence cancer susceptibility and progression.

Our study had some limitations. First, moderate or substantial heterogeneity was detected between studies, which was not significantly decreased by subgroup analysis. When all variations were included in the meta-regression analysis, no obvious factors were detected. More subgroup analyses should be performed, based on factors such as tobacco or alcohol consumption. This conclusion should be interpreted with caution. Second, this analysis was performed with candidate gene strategy in which the MMP1–1607 (1G>2G) polymorphism was selected for study based on a priori knowledge of the gene’s biological functional impact on the trait or disease in question [92]. Genome-wide association studies (GWAS) which scan the entire genome for genetic variation include immense amounts of SNPs. Published papers usually reported those SNPs with highly statistical significance (usually ). We have retrieved literature through PubMed in order to search the evidence of association between the MMP1–1607 (1G>2G) polymorphism and cancer risks in GWAS results [92, 93]. However, we did not acquire any positive findings. We speculate that ethnic discrepancy, population stratification, and different standards of statistical significance might lead to negative findings in GWAS. Third, due to the innate shortage of case–control designed studies, the quantity of studies was limited. Third, gene–gene and gene–environment interactions should be considered in analyses of the effects of genes. Fourth, more original papers with large sample sizes were required due to lack of eligible studies in specific cancers in this analysis.

5. Conclusions

In conclusion, an association between the MMP1–1607 (1G>2G) polymorphism and cancer risks was detected in both Asians and Caucasians. After stratification by cancer types, associations were found for lung cancer, colorectal cancer, nervous system cancer, renal cancer, bladder cancer, and nasopharyngeal cancer. More original studies with larger sample size are required for future analysis.

Conflicts of Interest

The authors declare no competing financial interests.

Acknowledgments

This study was partly funded by the National Natural Science Foundation of China (Grant No. NSFC 81502195 and NSFC 81672512) and Medicine and Health Science Technology Development Project of Shandong Province (No. 2016WS0258). We thank Liwen Bianji, Edanz Group China (http://www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

References

  1. G. L. Bond and A. J. Levine, “A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans,” Oncogene, vol. 26, no. 9, pp. 1317–1323, 2007. View at: Publisher Site | Google Scholar
  2. J. Decock, S. Thirkettle, L. Wagstaff, and D. R. Edwards, “Matrix metalloproteinases: protective roles in cancer,” Journal of Cellular and Molecular Medicine, vol. 15, no. 6, pp. 1254–1265, 2011. View at: Publisher Site | Google Scholar
  3. L. Tao, Z. Li, L. Lin et al., “MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis,” Genetic Testing and Molecular Biomarkers, vol. 19, no. 10, pp. 548–555, 2015. View at: Publisher Site | Google Scholar
  4. L. Wang and B. Kong, “Analysis of the association of matrix metalloproteinase-1 gene promoter (rs1799750) polymorphism and risk of ovarian cancer,” International Journal of Gynecological Cancer, vol. 25, no. 6, pp. 961–967, 2015. View at: Publisher Site | Google Scholar
  5. G. Han, Z. Wei, Z. Lu et al., “Association between matrix metalloproteinase 1–1607 1G>2G polymorphism and cancer risk: a meta-analysis including 19706 subjects,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 9, pp. 2992–2999, 2014. View at: Google Scholar
  6. L. Lu, Y. Sun, Y. Li, and P. Wan, “The polymorphism MMP1 −1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis,” Tumour Biology, vol. 36, no. 3, pp. 1685–1693, 2015. View at: Publisher Site | Google Scholar
  7. Y. Kanamori, M. Matsushima, T. Minaguchi et al., “Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region,” Cancer Research, vol. 59, no. 17, pp. 4225–4227, 1999. View at: Google Scholar
  8. M. L. Biondi, O. Turri, S. Leviti et al., “MMP1 and MMP3 polymorphisms in promoter regions and cancer,” Clinical Chemistry, vol. 46, no. 12, pp. 2023-2024, 2000. View at: Google Scholar
  9. Y. Nishioka, K. Kobayashi, S. Sagae et al., “A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas,” Japanese Journal of Cancer Research, vol. 91, no. 6, pp. 612–615, 2000. View at: Publisher Site | Google Scholar
  10. S. Ye, S. Dhillon, S. J. Turner et al., “Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism,” Cancer Research, vol. 61, no. 4, pp. 1296–1298, 2001. View at: Google Scholar
  11. Y. Zhu, M. R. Spitz, L. Lei, G. B. Mills, and X. Wu, “A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility,” Cancer Research, vol. 61, no. 21, pp. 7825–7829, 2001. View at: Google Scholar
  12. G. Ghilardi, M. L. Biondi, M. Caputo et al., “A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility,” Clinical Cancer Research, vol. 8, no. 12, pp. 3820–3823, 2002. View at: Google Scholar
  13. Y. Hinoda, N. Okayama, N. Takano et al., “Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer,” International Journal of Cancer, vol. 102, no. 5, pp. 526–529, 2002. View at: Publisher Site | Google Scholar
  14. H. Hirata, K. Naito, S. Yoshihiro, H. Matsuyama, Y. Suehiro, and Y. Hinoda, “A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma,” International Journal of Cancer, vol. 106, no. 3, pp. 372–374, 2003. View at: Publisher Site | Google Scholar
  15. Y. Nishioka, S. Sagae, A. Nishikawa, S. I. Ishioka, and R. Kudo, “A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression,” Cancer Letters, vol. 200, no. 1, pp. 49–55, 2003. View at: Publisher Site | Google Scholar
  16. R. M. Wenham, B. Calingaert, S. Ali et al., “Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer,” Journal of the Society for Gynecologic Investigation, vol. 10, no. 6, pp. 381–387, 2003. View at: Publisher Site | Google Scholar
  17. T. Hashimoto, K. Uchida, N. Okayama et al., “Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma,” Cancer Letters, vol. 211, no. 1, pp. 19–24, 2004. View at: Publisher Site | Google Scholar
  18. H. Hirata, N. Okayama, K. Naito et al., “Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma,” Carcinogenesis, vol. 25, no. 12, pp. 2379–2384, 2004. View at: Publisher Site | Google Scholar
  19. S. C. Lin, M. Y. Chung, J. W. Huang, T. M. Shieh, C. J. Liu, and K. W. Chang, “Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas,” Journal of Oral Pathology & Medicine, vol. 33, no. 6, pp. 323–326, 2004. View at: Publisher Site | Google Scholar
  20. S. Matsumura, N. Oue, Y. Kitadai et al., “A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 5, pp. 259–265, 2004. View at: Publisher Site | Google Scholar
  21. F. Zinzindohoué, H. Blons, S. Hans et al., “Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma,” Anticancer Research, vol. 24, no. 3b, pp. 2021–2026, 2004. View at: Google Scholar
  22. S. Fang, X. Jin, R. Wang et al., “Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China,” Carcinogenesis, vol. 26, no. 2, pp. 481–486, 2005. View at: Publisher Site | Google Scholar
  23. X. Jin, G. Kuang, L. Z. Wei et al., “No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China,” World Journal of Gastroenterology, vol. 11, no. 16, pp. 2385–2389, 2005. View at: Publisher Site | Google Scholar
  24. W. Ju, S. Kang, J. W. Kim et al., “Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women,” Cancer Letters, vol. 217, no. 2, pp. 191–196, 2005. View at: Publisher Site | Google Scholar
  25. H. C. Lai, C. M. Chu, Y. W. Lin et al., “Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer,” Gynecologic Oncology, vol. 96, no. 2, pp. 314–319, 2005. View at: Publisher Site | Google Scholar
  26. J. McCready, W. C. Broaddus, V. Sykes, and H. L. Fillmore, “Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma,” International Journal of Cancer, vol. 117, no. 5, pp. 781–785, 2005. View at: Publisher Site | Google Scholar
  27. Z. G. Cao and C. Z. Li, “A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population,” Oral Oncology, vol. 42, no. 1, pp. 32–38, 2006. View at: Publisher Site | Google Scholar
  28. N. Elander, P. Soderkvist, and K. Fransen, “Matrix metalloproteinase (MMP) -1, −2, −3 and −9 promoter polymorphisms in colorectal cancer,” Anticancer Research, vol. 26, no. 1b, pp. 791–795, 2006. View at: Google Scholar
  29. A. K. Kader, L. Shao, C. P. Dinney et al., “Matrix metalloproteinase polymorphisms and bladder cancer risk,” Cancer Research, vol. 66, no. 24, pp. 11644–11648, 2006. View at: Publisher Site | Google Scholar
  30. Y. Li, X. Jin, S. Kang et al., “Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China,” Gynecologic Oncology, vol. 101, no. 1, pp. 92–96, 2006. View at: Publisher Site | Google Scholar
  31. A. Lièvre, members of the ANGH group, J. Milet et al., “Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma,” BMC Cancer, vol. 6, no. 1, 2006. View at: Publisher Site | Google Scholar
  32. P. O-charoenrat, P. Leksrisakul, and S. Sangruchi, “A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer,” International Journal of Cancer, vol. 118, no. 10, pp. 2548–2553, 2006. View at: Publisher Site | Google Scholar
  33. L. Su, W. Zhou, K. Asomaning et al., “Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer,” Carcinogenesis, vol. 27, no. 5, pp. 1024–1029, 2006. View at: Publisher Site | Google Scholar
  34. M. Sugimoto, S. Yoshida, S. Kennedy, M. Deguchi, N. Ohara, and T. Maruo, “Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population,” Journal of the Society for Gynecologic Investigation, vol. 13, no. 7, pp. 523–529, 2006. View at: Publisher Site | Google Scholar
  35. E. Xu, M. Lai, B. Lŭ, X. Xing, and Q. Huang, “No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese,” Diseases of the Colon and Rectum, vol. 49, no. 9, pp. 1439–1444, 2006. View at: Publisher Site | Google Scholar
  36. S. Albayrak, Ö. Cangüven, C. Göktaş, H. Aydemir, and V. Köksal, “Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population,” Urologia Internationalis, vol. 79, no. 4, pp. 312–315, 2007. View at: Publisher Site | Google Scholar
  37. W. Ju, J. W. Kim, N. H. Park et al., “Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer: does ethnicity matter?” The Journal of Obstetrics and Gynaecology Research, vol. 33, no. 2, pp. 155–160, 2007. View at: Publisher Site | Google Scholar
  38. H. Lei, K. Hemminki, A. Altieri et al., “Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression,” Breast Cancer Research and Treatment, vol. 103, no. 1, pp. 61–69, 2007. View at: Publisher Site | Google Scholar
  39. Z. Lu, Y. Cao, Y. Wang et al., “Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China,” Journal of Neuro-Oncology, vol. 85, no. 1, pp. 65–73, 2007. View at: Publisher Site | Google Scholar
  40. H. B. Nasr, S. Mestiri, K. Chahed et al., “Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas,” Clinica Chimica Acta, vol. 384, no. 1-2, pp. 57–63, 2007. View at: Publisher Site | Google Scholar
  41. R. Nishizawa, M. Nagata, A. A. Noman et al., “The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma,” BMC Cancer, vol. 7, no. 1, 2007. View at: Publisher Site | Google Scholar
  42. M. F. Piccoli, M. Figueira, C. Andreoni, J. T. Marumo, N. Schor, and M. H. Bellini, “Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma,” International Braz J Urol, vol. 33, no. 5, pp. 622–629, 2007. View at: Publisher Site | Google Scholar
  43. E. Vairaktaris, C. Yapijakis, S. Derka et al., “Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma,” Anticancer Research, vol. 27, no. 1A, pp. 459–464, 2007. View at: Google Scholar
  44. M. Woo, K. Park, J. Nam, and J. C. Kim, “Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer,” Journal of Gastroenterology and Hepatology, vol. 22, no. 7, pp. 1064–1070, 2007. View at: Publisher Site | Google Scholar
  45. Y. Zhai, W. Qiu, X. J. Dong et al., “Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk,” Gut, vol. 56, no. 3, pp. 445–447, 2007. View at: Publisher Site | Google Scholar
  46. G. Zhou, Y. Zhai, Y. Cui et al., “Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma,” Human Mutation, vol. 28, no. 11, pp. 1091–1097, 2007. View at: Publisher Site | Google Scholar
  47. S. T. Dos Reis, F. E. Villanova, P. M. de Andrade et al., “Polymorphisms of the matrix metalloproteinases associated with prostate cancer,” Molecular Medicine Reports, vol. 1, no. 4, pp. 517–520, 2008. View at: Google Scholar
  48. P. González-Arriaga, M. F. López-Cima, A. Fernández-Somoano et al., “Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk,” BMC Cancer, vol. 8, no. 1, 2008. View at: Publisher Site | Google Scholar
  49. F. Kouhkan, M. Motovali-Bashi, and Z. Hojati, “The influence of interstitial collagenas-1 genotype polymorphism on colorectal cancer risk in Iranian population,” Cancer Investigation, vol. 26, no. 8, pp. 836–842, 2009. View at: Publisher Site | Google Scholar
  50. Y. Shimizu, S. Kondo, A. Shirai, M. Furukawa, and T. Yoshizaki, “A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer,” Auris Nasus Larynx, vol. 35, no. 3, pp. 381–389, 2008. View at: Publisher Site | Google Scholar
  51. A. I. Tasci, V. Tugcu, E. Ozbek, B. Ozbay, A. Simsek, and V. Koksal, “A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility,” BJU International, vol. 35, no. 3, pp. 381–389, 2007. View at: Publisher Site | Google Scholar
  52. P. A. Bradbury, R. Zhai, J. Hopkins et al., “Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis,” Carcinogenesis, vol. 30, no. 5, pp. 793–798, 2009. View at: Publisher Site | Google Scholar
  53. J. M. de Lima, L. G. de Souza, I. D. C. G. da Silva, and N. M. Forones, “E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer,” The International Journal of Biological Markers, vol. 24, no. 2, pp. 99–106, 2018. View at: Publisher Site | Google Scholar
  54. S. T. dos Reis, J. Pontes Jr, F. E. Villanova et al., “Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer,” The Journal of Urology, vol. 181, no. 5, pp. 2320–2325, 2009. View at: Publisher Site | Google Scholar
  55. C. Ricketts, M. P. Zeegers, J. Lubinski, and E. R. Maher, “Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma,” PLoS One, vol. 4, no. 6, article e6037, 2009. View at: Publisher Site | Google Scholar
  56. P. Srivastava, R. Kapoor, and R. D. Mittal, “Influence of matrix metalloproteinase gene polymorphisms in healthy North Indians compared to variations in other ethnic groups worldwide,” Asian Pacific Journal of Cancer Prevention, vol. 10, no. 6, pp. 1127–1130, 2009. View at: Google Scholar
  57. N. Tsuchiya, S. Narita, T. Kumazawa et al., “Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer,” Oncology Reports, vol. 22, no. 3, pp. 493–499, 2009. View at: Google Scholar
  58. E. Vairaktaris, Z. Serefoglou, D. Avgoustidis et al., “Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer,” Oral Oncology, vol. 45, no. 3, pp. 247–253, 2009. View at: Publisher Site | Google Scholar
  59. M. Altaş, O. F. Bayrak, E. Ayan et al., “The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma,” Acta Neurochirurgica, vol. 152, no. 9, pp. 1611–1617, 2010. View at: Publisher Site | Google Scholar
  60. A. K. Chaudhary, M. Singh, A. C. Bharti, K. Asotra, S. Sundaram, and R. Mehrotra, “Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck,” Journal of Biomedical Science, vol. 17, no. 1, p. 10, 2010. View at: Publisher Site | Google Scholar
  61. W. L. Fang, W. B. Liang, H. He et al., “Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population,” DNA and Cell Biology, vol. 29, no. 11, pp. 657–661, 2010. View at: Publisher Site | Google Scholar
  62. K. Okamoto, C. Ishida, Y. Ikebuchi et al., “The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma,” Internal Medicine, vol. 49, no. 10, pp. 887–895, 2010. View at: Publisher Site | Google Scholar
  63. K. Hart, N. E. Landvik, H. Lind, V. Skaug, A. Haugen, and S. Zienolddiny, “A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer,” Lung Cancer, vol. 71, no. 2, pp. 123–129, 2011. View at: Publisher Site | Google Scholar
  64. L. Liu, J. Wu, C. Wu et al., “A functional polymorphism (−1607 1G-->2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer,” Cancer, vol. 117, no. 22, pp. 5172–5181, 2011. View at: Publisher Site | Google Scholar
  65. N. Malik, R. Kumar, K. N. Prasad, P. Kawal, A. Srivastava, and A. K. Mahapatra, “Association of matrix metalloproteinase-1 gene polymorphism with glioblastoma multiforme in a northern Indian population,” Journal of Neuro-Oncology, vol. 102, no. 3, pp. 347–352, 2011. View at: Publisher Site | Google Scholar
  66. L. E. Wang, Y. J. Huang, M. Yin et al., “Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma,” European Journal of Cancer, vol. 47, no. 1, pp. 107–115, 2011. View at: Publisher Site | Google Scholar
  67. W. Y. Cheung, R. Zhai, P. Bradbury et al., “Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma,” International Journal of Cancer, vol. 131, no. 11, pp. 2478–2486, 2012. View at: Publisher Site | Google Scholar
  68. L. Enewold, L. E. Mechanic, E. D. Bowman, E. A. Platz, and A. J. Alberg, “Association of matrix metalloproteinase-1 polymorphisms with risk of COPD and lung cancer and survival in lung cancer,” Anticancer Research, vol. 32, no. 9, pp. 3917–3922, 2012. View at: Google Scholar
  69. H. Fakhoury, S. Noureddine, H. N. Chmaisse, H. Tamim, and R. F. Makki, “MMP1-1607(1G>2G) polymorphism and the risk of lung cancer in Lebanon,” Annals of Thoracic Medicine, vol. 7, no. 3, pp. 130–132, 2012. View at: Publisher Site | Google Scholar
  70. E. Wieczorek, E. Reszka, Z. Jablonowski et al., “Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility,” BJU International, vol. 112, no. 8, pp. 1207–1214, 2013. View at: Publisher Site | Google Scholar
  71. K. Brzóska, T. Bartłomiejczyk, B. Sochanowicz et al., “Matrix metalloproteinase 3 polymorphisms as a potential marker of enhanced susceptibility to lung cancer in chronic obstructive pulmonary disease subjects,” Annals of Agricultural and Environmental Medicine, vol. 21, no. 3, pp. 546–551, 2014. View at: Publisher Site | Google Scholar
  72. H. Dedong, Z. Bin, S. Peisheng, X. Hongwei, and Y. Qinghui, “The contribution of the genetic variations of the matrix metalloproteinase-1 gene to the genetic susceptibility of gastric cancer,” Genetic Testing and Molecular Biomarkers, vol. 18, no. 10, pp. 675–682, 2014. View at: Publisher Site | Google Scholar
  73. K. Devulapalli, A. C. Bhayal, S. K. Porike et al., “Role of interstitial collagenase gene promoter polymorphism in the etiology of gastric cancer,” Saudi Journal of Gastroenterology, vol. 20, no. 5, pp. 309–314, 2014. View at: Publisher Site | Google Scholar
  74. S. Dey, N. Ghosh, D. Saha, K. Kesh, A. Gupta, and S. Swarnakar, “Matrix metalloproteinase-1 (MMP-1) promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population,” PLoS One, vol. 9, no. 2, article e88040, 2014. View at: Publisher Site | Google Scholar
  75. X. Guan, X. Wang, H. Luo, J. Wu, X. Zhang, and J. Wu, “Matrix metalloproteinase 1, 3, and 9 polymorphisms and esophageal squamous cell carcinoma risk,” Medical Science Monitor, vol. 20, pp. 2269–2274, 2014. View at: Publisher Site | Google Scholar
  76. P. Kawal, A. Chandra, Rajkumar, T. N. Dhole, and B. Ojha, “Correlations of polymorphisms in matrix metalloproteinase-1, -2, and -7 promoters to susceptibility to malignant gliomas,” Asian Journal of Neurosurgery, vol. 11, no. 2, pp. 160–166, 2016. View at: Publisher Site | Google Scholar
  77. J.-S. Pei, P.-C. Hsu, A.-K. Chou et al., “Matrix metalloproteinase-1 genotype contributes to the risk of non-solid tumor in childhood leukemia,” Anticancer Research, vol. 36, no. 10, pp. 5127–5132, 2016. View at: Publisher Site | Google Scholar
  78. C. H. Su, H. Y. Lane, C. L. Hsiao et al., “Matrix metalloproteinase-1 genetic polymorphism in breast cancer in Taiwanese,” Anticancer Research, vol. 36, no. 7, pp. 3341–3345, 2016. View at: Google Scholar
  79. K. T. Sun, C. W. Tsai, W. S. Chang et al., “The contribution of matrix metalloproteinase-1 genotype to oral cancer susceptibility in Taiwan,” In Vivo, vol. 30, no. 4, pp. 439–444, 2016. View at: Google Scholar
  80. C. W. Tsai, W. S. Chang, C. L. Gong et al., “Contribution of matrix metallopeptidase-1 genotypes, smoking, Alcohol Drinking and Areca Chewing to Nasopharyngeal Carcinoma Susceptibility,” Anticancer Research, vol. 36, no. 7, pp. 3335–3340, 2016. View at: Google Scholar
  81. Y. L. Lai, C. L. Gong, C. K. Fu et al., “The contribution of matrix metalloproteinase-1 genotypes to hepatocellular carcinoma susceptibility in Taiwan,” Cancer Genomics Proteomics, vol. 14, no. 2, pp. 119–126, 2017. View at: Publisher Site | Google Scholar
  82. C. Padala, M. A. Tupurani, K. Puranam et al., “Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer,” PLoS One, vol. 12, no. 9, article e0184448, 2017. View at: Publisher Site | Google Scholar
  83. M. D. Yang, K. C. Lin, M. C. Lu et al., “Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan,” BioMedicine, vol. 7, no. 2, p. 10, 2017. View at: Publisher Site | Google Scholar
  84. X. M. Zhu and W. F. Sun, “Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: a meta-analysis and systematic review,” PLoS One, vol. 12, no. 9, article e0185456, 2017. View at: Publisher Site | Google Scholar
  85. Z. Li, H. Ge, Y. G. Xie, G. Y. Xie, and C. Lv, “Matrix metalloproteinase-1 (MMP1) polymorphism is associated with lowered risk of nasopharyngeal carcinoma in Asian population,” Cell Biochemistry and Biophysics, vol. 71, no. 2, pp. 999–1004, 2015. View at: Publisher Site | Google Scholar
  86. H. Li, X. Liang, X. Qin, S. Cai, and S. Yu, “Association of matrix metalloproteinase family gene polymorphisms with lung cancer risk: logistic regression and generalized odds of published data,” Scientific Reports, vol. 5, no. 1, 2015. View at: Publisher Site | Google Scholar
  87. X. Li, L. Qu, Y. Zhong, Y. Zhao, H. Chen, and L. Daru, “Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 9, pp. 1433–1447, 2013. View at: Publisher Site | Google Scholar
  88. S. R. Ji, J. J. Sun, X. P. Li, Y. Zhang, and W. F. Liu, “The association of matrix metalloproteinase-1 genetic polymorphism (−1607 1G>2G) with colorectal cancer: a meta-analysis,” Tumour Biology, vol. 34, no. 6, pp. 3801–3806, 2013. View at: Publisher Site | Google Scholar
  89. J. Y. Li, J. Chang, J. B. Tian et al., “A rare variant P507L in TPP1 interrupts TPP1-TIN2 interaction, influences telomere length, and confers colorectal cancer risk in Chinese population,” Cancer Epidemiology, Biomarkers & Prevention, vol. 27, no. 9, pp. 1029–1035, 2018. View at: Publisher Site | Google Scholar
  90. D. Y. Zou, J. Lou, J. T. Ke et al., “Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression,” European Journal of Cancer, vol. 93, no. 1, pp. 1–9, 2018. View at: Publisher Site | Google Scholar
  91. J. Chang, J. B. Tian, Y. Yang et al., “A rare missense variant in TCF7L2 associates with colorectal cancer risk by interacting with a GWAS-identified regulatory variant in the MYC enhancer,” Cancer Research, vol. 78, no. 17, pp. 5164–5172, 2018. View at: Publisher Site | Google Scholar
  92. E. Y. Bae, S. Y. Lee, B. K. Kang et al., “Replication of results of genome-wide association studies on lung cancer susceptibility loci in a Korean population,” Respirology, vol. 17, no. 4, pp. 699–706, 2012. View at: Publisher Site | Google Scholar
  93. M. P. Purdue, Y. Ye, Z. Wang et al., “A genome-wide association study of renal cell carcinoma among African Americans,” Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 1, pp. 209–214, 2014. View at: Publisher Site | Google Scholar

Copyright © 2018 Zhonghan Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

639 Views | 240 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.